Overview

This trial is active, not recruiting.

Condition trachoma
Treatments surveillance and treatment with azithromycin of newcomer and traveler families, usual care
Phase phase 4
Sponsor Johns Hopkins University
Collaborator National Eye Institute (NEI)
Start date January 2013
End date December 2015
Trial size 52 participants
Trial identifier NCT01767506, NA_00076305, U10EY022584

Summary

Infection with C. Trachomatis has decreased substantially in trachoma endemic areas following repeated annual mass drug administration (MDA) with azithromycin, although not as rapidly as anticipated. The investigators propose to conduct a clinical trial in 52 communities in Kongwa, Tanzania that on average have trachoma infection at 3.5%. The investigators plan that all communities would have annual rounds of MDA if infection is greater than 1% or follicular trachoma (TF) is 5% or more, but half would be randomized to a surveillance and treatment program to identify and treat new families and families who travel after mass treatment. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. The proportion of communities that are able to stop mass treatment will be compared in the group of communities randomized to mass treatment plus the newcomer/traveler treatment program compared to the communities randomized to mass treatment alone after 24 months.

At the recommendation of the Data Safety and Monitoring Committee in March 2015, thirty eight (38) of the 52 communities identified as being at risk of trachoma re-emergence at 18 months will be surveyed at 30 months. At risk of trachoma re-infection communities have C. trachomatis infection rates less than or equal to 1% or TF < 5% at the time of the 18 month survey. Surveillance of communities for families that meet the newcomer or traveler status will extend 6 months beyond the 24 month survey to 30 months in the intervention communities only. A survey of sentinel children in the intervention and control communities at 30 months will be conducted to assess the level of trachoma and infection in all 38 communities at risk of trachoma re-emergence.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
surveillance and treatment with azithromycin of newcomer and traveler families Zithromax
The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
usual care Zithromax
Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
(Active Comparator)
Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
usual care Zithromax
Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.

Primary Outcomes

Measure
The proportion of communities with C. trachomatis infection prevalence of 1% or below
time frame: 24 months

Secondary Outcomes

Measure
The proportion of communities with clinical trachoma prevalence of 5% or below
time frame: 24 months
The trajectory of change in prevalence of infection with C. trachomatis and clinical trachoma
time frame: Baseline to 24 months
The community prevalence of new infections of C. trachomatis and clinical trachoma identified
time frame: 24 months
The presence of active trachoma in children
time frame: Baseline only
The presence of trachomatous scarring in women
time frame: Baseline only

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: Census and Mass Drug Administration (MDA): All persons residing in the 52 study communities will be eligible for both the census and the annual mass azithromycin administrations. Intervention: In the 26 intervention communities, active surveillance for new families and returning travelers will be undertaken, and those meeting the criteria below will be eligible for family treatment with azithromycin if: Families are "newcomers" and - They have children under 10 years of age - They have moved into a new house in the community or into an existing household - They plan to reside for at least 1 month in the study community and - They have moved from a community that has not had an MDA in the last year Families are classified as having traveled and - They have children under 10 years of age - They participated in a previous census in the same community - They left the community for at least 8 weeks (2 months) for an area that has not received MDA in the past year and at least one child has returned and - They have returned to reside in the community for at least 2 months Sentinel Children: In all 52 communities, samples of 135 children will be selected from the community census lists every six months for survey and examination. These children: - must be between 1 year and 9.9 years of age, - must be a resident in the community and not a short-term (less than 2 months) visitor, - must not have an ocular condition that would preclude grading trachoma or taking an ocular specimen, - must be willing to have a swab taken as part of being a sentinel child (this is critical, as each swab result counts towards the criteria for stopping MDA), and - must have an identifiable guardian capable of providing consent to participate. Adult Women: In all 52 communities, samples of 100 women will be selected from the baseline community census list. These women: - must be aged 15 years and over - must be a resident in the community and not a short term (less than 2 months) visitor - must not have an ocular condition that precludes grading of scarring on upper conjunctiva - must be able to provide informed consent. Exclusion Criteria:

Additional Information

Official title A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Principal investigator Sheila K West, PhD
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Johns Hopkins University.